David Flaherty, PhD is a Professor in the School of Chemical and Biomolecular Engineering at Georgia Tech since June 2023 (starting Summer 2023, previously at the University of Illinois, Urbana-Champaign). His research focuses on developing the science and application of catalysis in the pursuit of sustainability. In recent years, his group’s contributions have been featured in Science, Nature Catalysis, Journal of the American Chemical Society, ACS Catalysis, Journal of Catalysis and other prestigious journals. Dr. Flaherty has received several recognitions for excellence and innovation in catalysis including the Eastman Foundation Distinguished Lecturer in Catalysis, Department of Energy Early Career Award, and the National Science Foundation CAREER Award. Dr. Flaherty engages frequently with industry to translate the groups scientific achievements from the lab into practice. Through university-industry partnerships, the group has filed multiple patents disclosing synthesis of catalytic materials and development of processes. Beyond his research activities, Dr. Flaherty enjoys teaching topics in chemical engineering in the classroom (kinetics, separations, transport, reaction engineering) and mentoring the next generation of research leaders and educators.

Prof. Flaherty received his B.S. in Chemical Engineering from the University of California, Berkeley and his Ph.D. in Chemical Engineering from the University of Texas at Austin under the direction of Prof. C. Buddie Mullins. He conducted postdoctoral work at the University of California, Berkeley with Prof. Enrique Iglesia.

Michael Filler is a professor and the Traylor Faculty Fellow in the School of Chemical and Biomolecular Engineering at the Georgia Institute of Technology. He earned his undergraduate and graduate degrees from Cornell University and Stanford University, respectively, prior to completing postdoctoral studies at the California Institute of Technology. Filler has been recognized for his research and teaching with the National Science Foundation CAREER Award, Georgia Tech Sigma Xi Young Faculty Award, CETL/BP Junior Faculty Teaching Excellence Award, and AVS Dorothy M. and Earl S. Hoffman Award. Filler also heads Nanovation, a forum to address the big questions, big challenges, and big opportunities of nanotechnology.

Lily Cheung got her research start as a sophomore at Rutgers University, where she graduated Summa Cum Laude with a B.S. in Chemical Engineering in 2008. She then earned her Ph.D. in Chemical Engineering from Princeton University in 2013. Under the supervision of Stanislav Shvartsman, she characterized gene regulatory networks controlling the development of the model organism Drosophila melanogaster, using a combination of molecular biology, genetics, and reaction-diffusion modeling.

During her postdoctoral training with Wolf Frommer at the Carnegie Institution for Science, she designed biomolecular sensors to quantify sugar transport in plants. Her current interests include the use of high-throughput quantitative techniques and mathematical modeling to advance our understanding of how metabolic and gene regulatory networks interact to control plant growth.

Lily is the recipient of a NSF NPGI Postdoctoral Fellowship in Biology, a NSF CAREER Award, and a Human Frontier Science Program Early Career Award.

Dr. Chance retired from Global Thermostat at the end of 2022, where he served as a Senior Science Advisor. He continues at the Georgia Institute of Technology where he serves as an Adjunct Professor. Dr. Chance began his career with Honeywell Corporation, holding a number of research positions including Research Manager for Electronic Materials.

In 1986, he joined Exxon as the Director of their Polymers and Fluids Laboratory, later serving as Division Manager for their Paramins Technology division, and as Distinguished Scientific Advisor in ExxonMobil’s Corporate Strategic Research Laboratories. Dr. Chance retired from ExxonMobil in 2006 and joined the Georgia Institute of Technology as a faculty member with a joint appointment in the School of Chemical and Biomolecular Engineering and the School of Chemistry and Biochemistry, continuing also as Distinguished Scientific Advisor Emeritus at ExxonMobil from 2006-2009. 

He joined Algenol Biofuels (2009-2019) as Executive Vice President for Engineering. Dr. Chance's scientific interests are focused on CO² capture and utilization, including Direct Air Capture, as a mitigation strategy for climate change. 

Dr. Chance has organized several international scientific meetings and served on numerous university and industrial advisory boards. He has published over 150 peer-reviewed articles, edited two books, and authored over 30 patents. He was elected Fellow in The American Physical Society in 1988 and was the 2018 recipient of the Lawrence B. Evans Award from the American Institute of Chemical Engineers, an institute level award for career achievement.

Julie Champion is the William R. McLain Endowed Term Professor in the School of Chemical and Biomolecular Engineering at Georgia Institute of Technology. She earned her B.S.E. in chemical engineering from the University of Michigan and Ph.D. in chemical engineering at the University of California Santa Barbara. She was an NIH postdoctoral fellow at the California Institute of Technology. Champion is a fellow of the American Institute for Medical and Biological Engineering and has received awards including American Chemical Society Women Chemists Committee Rising Star, NSF BRIGE Award, Georgia Tech Women in Engineering Faculty Award for Excellence in Teaching, Georgia Tech BioEngineering Program Outstanding Advisor Award. Professor Champion’s current research focuses on design and self-assembly of functional nanomaterials made from engineered proteins for applications in immunology, cancer, and biocatalysis.

Andreas (Andy) S. Bommarius is a professor of Chemical and Biomolecular Engineering as well of Chemistry and Biochemistry at the Georgia Institute of Technology in Atlanta, GA.  He received his diploma in Chemistry in 1984 at the Technical University of Munich, Germany and his Chemical Engineering B.S. and Ph.D. degrees in 1982 and 1989 at MIT, Cambridge, MA.

From 1990-2000, he led the Laboratory of Enzyme Catalysis at Degussa (now Evonik) in Wolfgang, Germany, where his work ranged from immobilizing homogenous catalysts in membrane reactors to large-scale cofactor-regenerated redox reactions to pharma intermediates.

At Georgia Tech since 2000, his research interests cover green chemistry and biomolecular engineering, specifically biocatalyst development and protein stability studies.  His lab applies data-driven protein engineering to improve protein properties on catalysts ranging from ene and nitro reductases to cellobiohydrolases.  Bommarius has guided the repositioning of the curriculum towards Chemical and Biomolecular Engineering by developing new courses in Process Design, Biocatalysis and Metabolic Engineering, as well as Drug Design, Development, and Delivery (D4), an interdisciplinary course with Mark Prausnitz.

Andy Bommarius in 2008 became a Fellow of the American Institute of Medical and Biological Engineering.  Since 2010, he is Director of the NSF-I/UCR Center for Pharmaceutical Development (CPD), a Center focusing on process development, drug substance and product stability, and novel analytical methods for the characterization of drug substances and excipients.

The Blazeck Lab tackles challenges at the interface of immunology, engineering, and metabolism to improve human health. We utilize our expertise in cellular and protein engineering to control biological function and to develop novel therapies to fight disease.

Synthetic Immune Systems

Our immune system uses very complex processes to make exquisitely specific receptors that recognize disease causing agents, and much of our ability to fight diseases is contingent upon the development of a diverse repertoire of immune receptors. Many questions remain unanswered about these immune receptors. For instance, at a population level, can we characterize the millions of receptors each person makes? And then further determine which of these millions of receptors is most important towards recognizing and targeting a pathogen? And can we control the generation of immune receptors to have desired properties? We are striving to answer these questions by harnessing our immune system’s power in a synthetic setting to improve understanding and treatment options for numerous diseases, while developing applications for vaccine design, personalized medicine, and enzyme engineering.

Engineering Cellular Therapies

Immunotherapies are treatments designed to modulate the immune response that have shown astounding clinical potential, yet there are no current treatments with guaranteed success. We are working to engineer cellular systems with controllable, enhanced, and non-native functions that improve their impact and capability. By developing high throughput technologies to interrogate immune function, we hope to translate our findings into improvements in the next generation of cellular therapeutics. 

Developing Proteins that Fight Cancer and Control Metabolism

It is widely accepted that cancer cells have a significantly altered genomic and metabolic makeup relative to normal cells, but how can we best target these differences? By combining our expertise in metabolism and therapeutic protein engineering, are working to engineer proteins to directly target and fight cancer. For instance, certain enzymes can control the metabolic environment around tumors to inhibit their growth or to stimulate a native anti-cancer immune response. We utilize directed evolution approaches to optimize protein function and efficacy.

Saad Bhamla studies biomechanics across species to engineer knowledge and tools that inspire curiosity.

Saad Bhamla is an assistant professor of biomolecular engineering at Georgia Tech. A self-proclaimed "tinkerer," his lab is a trove of discoveries and inventions that span biology, physics and engineering. His current projects include studying the hydrodynamics of insect urine, worm blob locomotion and ultra-low-cost devices for global health. His work has appeared in the New York Times, the Economist, CNN, Wired, NPR, the Wall Street Journal and more.

Saad is a prolific inventor and his most notable inventions includes a 20-cent paper centrifuge, a 23-cent electroporator, and the 96-cent hearing aid. Saad's work is recognised by numerous awards including a NIH R35 Outstanding Investigator Award, NSF CAREER Award, CTL/BP Junior Faculty Teaching Excellence Award, and INDEX: Design to Improve Life Award. Saad is also a National Geographic Explorer and a TED speaker. Newsweek recognized Saad as 1 of 10 Innovators disrupting healthcare.

Saad is a co-founder of Piezo Therapeutics.

Outside of the lab, Saad loves to go hiking with his partner and two dogs (Ollie and Bella).